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Abstract 
Background: RNA–protein interactions play important roles in gene expression control. These interactions are medi-
ated by several recurring RNA-binding motifs including a well-known and characterized ribonucleoprotein motif or 
so-called RNA recognition motif (RRM).
Results: In the current study, we set out to identify the RNA ligand(s) of a RRM-containing protein Tip110, also known 
as p110nrb, SART3, or p110, using a RNA-based yeast three-hybrid cloning strategy. Six putative RNA targets were 
isolated and found to contain a consensus sequence that was identical to nucleotides 34–46 of U6 small nuclear RNA. 
Tip110 binding to U6 was confirmed to be specific and RRM-dependent in an electrophoretic mobility shift assay. 
Both in vitro pre-mRNA splicing assay and in vivo splicing-dependent reporter gene assay showed that the pre-mRNA 
splicing was correlated with Tip110 expression. Moreover, Tip110 was found in the spliceosomes containing pre-
spliced pre-mRNA and spliced mRNA products. Nonetheless, the RRM-deleted mutant (ΔRRM) that did not bind to 
U6 showed promotion in vitro pre-mRNA splicing, whereas the nuclear localization signal (NLS)-deleted mutant ΔNLS 
that bound to U6 promoted the pre-mRNA splicing both in vitro and in vivo. Lastly, RNA-Seq analysis confirmed that 
Tip110 regulated a number of gene pre-mRNA splicing including several splicing factors.
Conclusions: Taken together, these results demonstrate that Tip110 is directly involved in constitutive eukaryotic 
pre-mRNA splicing, likely through its binding to U6 and regulation of other splicing factors, and provide further evi-
dence to support the global roles of Tip110 in regulation of host gene expression.
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Background
In eukaryotic cells, gene expression begins in nucleus 
with transcription of protein-coding genes to primary 
RNA transcripts, or so-called pre-messenger RNA (pre-
mRNA) or heterogeneous nuclear RNA (hnRNA) [1]. 
The pre-mRNA are processed to become mature mRNA 
through a series of post-transcriptional modifications 
[2]. One of them is the precise excision of noncoding 
sequences (introns) from pre-mRNA in the spliceosomes 
[2]. The spliceosomes are formed through assem-
bly of spliceosomal small nuclear ribonucleoprotein 
(snRNP) and recruitment of numerous splicing factors 
to pre-mRNA [1, 2]. Efficient and proper pre-mRNA 
splicing is a critical step in gene expression control [3, 
4]. Dysregulation of splicing elements or splicing regula-
tors and subsequent abnormal pre-mRNA splicing result 
in expression of aberrant protein products and develop-
ment of diseases [3, 4]. For example, overexpression of 
splicing factor SF2/ASF has been shown to trigger malig-
nant transformation [5].
snRNP are important components of the spliceosomes 
in which the pre-mRNA splicing occurs [6]. There are five 
major snRNP U1, U2, U4, U5, and U6 in the spliceosomes 
containing small nuclear RNA (snRNA) U1 snRNA, U2 
snRNA, U4 snRNA, U5 snRNA, and U6 snRNA, respec-
tively [6]. Those snRNA are transcribed in the nucleus 
and exported to the cytoplasm after acquiring a m7G-
cap [1, 2]. The core snRNP are initially assembled in the 
cytoplasm to contain snRNA, survival motor neuron pro-
tein, Gem-associated proteins, and Sm proteins, followed 
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by nuclear import [7]. Once the core snRNP get into the 
nucleus, they enter the Cajal body, undergo further modi-
fications such as RNA-targeted ribose methylation and 
pseudouridylation, recruit additional proteins to complete 
its final assembly for pre-mRNA splicing [7]. One group of 
the best-defined proteins that snRNP recruit in the Cajal 
body are serine-/arginine-rich repeat (RS domain)-con-
taining splicing factors called SR proteins [8]. SR proteins 
are characterized by the presence of RNA recognition 
motifs (RRM) in the N terminus and the presence of RS 
domain in the C terminus. Most of the serine/arginine-
rich (SR) proteins are found in the nucleus, specifically in 
nuclear speckles, and are known for their roles in alterna-
tive and constitutive pre-mRNA splicing [9, 10]. Besides SR 
proteins, there are a number of other pre-mRNA splicing 
factors in the nuclear speckles. Those pre-mRNA splicing 
factors are constantly moving between nuclear speckles 
and the nucleoplasm or other nuclear substructures [11]. 
Nevertheless, nuclear speckles are often regarded as the 
sites for storage, assembly, and modification of the splic-
ing factors as well as the supply sources of splicing factors 
for active transcription sites [12–14]. In addition, nuclear 
speckles have been shown to be directly involved in the 
pre-mRNA splicing [15].
Tip110, also known as p110nrb, SART3, or p110, has 
been proposed to serve several important biological 
functions. These include tumor antigen function [16–
18], control of gene transcription [19–21], regulation of 
protein stability [22, 23], and stem cell pluripotency and 
differentiation [24–26]. In addition, Tip110 has been 
proposed to be directly involved in pre-mRNA splic-
ing through interaction with RNPS1 [16], U4/U6 snRNP 
[27, 28], YB-1 [29], and C-MYC [26]. In agreement with 
Tip110 roles in pre-mRNA splicing, Tip110 has two RNA 
recognition domains [16] and has been detected in the 
nuclear substructures Cajal bodies and nuclear speck-
les [14, 30, 31]. Further supporting Tip110 roles in pre-
mRNA splicing is the recent findings that Tip110 directly 
binds to unphosphorylated C-terminal domain (CTD) 
of RNA polymerase II in the direct manner [21]. In the 
current study, we set out to identify specific RNA tar-
gets, if any, that might be involved in interaction with 
Tip110 and account for Tip110 function in pre-mRNA 
splicing. We took advantage of the RNA–protein bind-
ing-based yeast three hybrid screening strategy and iden-
tified snRNA U6 from a hybrid RNA library as putative 
Tip110-binding partner. We then characterized the inter-
action and its role in pre-mRNA splicing.
Methods
Cell lines and cell transfection
293T and Hela cells were purchased from American Tis-
sue Culture Collection (ATCC, Manassas, VA, USA) and 
maintained in Dulbecco’s modified Eagle’s medium sup-
plemented with 10% fetal bovine serum, in a 37°C, 5% 
CO2 incubator. Cells were transfected using the standard 
calcium phosphate precipitation method.
Plasmids
Plasmids pTip110.His, pTip110s.His, and deletion 
mutants ΔNLS and ΔRRM, and pGEX-Tip110, pGEX-
Tip110s, and deletion mutants ΔNLS and ΔRRM, 
and pAD.Tip110 were described elsewhere [20]. The 
standard PCR cloning technique was used to construct 
pTip110ΔLSM, with pTip110.His as the templates and 
primers 5′-GGA ATT CAC CAT GGC GAC TGC GGC 
CGA A-3′ and 5′-CCG CTC GAG TCA ATG ATG ATG 
ATG ATG ATG GGC AAC TGC AGG AGC CG-3′ (the 
restriction enzyme sites underlined). The Tip110 siRNA 
expression plasmid was constructed in the backbone 
of pSHAG-1 by annealing oligonucleotides 5′-CGG 
GAT CCG ACT CAG CCT CGG GTT CTG AA-3′ and 
5′-CGG GAT CCA AAA AAT TGG ACT CAG CCT 
CA-3′, and inserting the annealed DNA at the Bam HI 
site of pSHAG-1. All recombinant plasmids and deletion 
mutants were verified by sequencing. The sources of the 
other plasmids used in the study are: pGEX-4T-3 from 
Amersham (Piscataway, NJ, USA), pSHAG-1 from Dr. 
Gregory Hannon, pIIIA.MS2 from Dr. Marvin Wickens, 
pT7.U6 from Dr. Iain Mattaji, pDM138 from Dr. Thomas 
Hope, pcRev from Dr. Bryan Cullen, and pSP64-Hβδ6 
from Dr. Adrian Krainer.
Construction of a hybrid RNA library and yeast 
three‑hybrid screening
A hybrid RNA library and yeast three-hybrid screening 
were performed as previously described [32], with some 
modifications. Briefly, genomic DNA was isolated from 
293T cells and digested by Mse I, Tsp509I, Alu I and 
Rsa I, and then by T4 DNA polymerase in the presence 
of 100 μM dNTP. Digested DNA was fractionated on a 
2% agarose gel to obtain DNA fragments of 50–150 bp. 
These small DNA fragments were then ligated into 
SmaI-linearized and calf intestine phosphatase-treated 
pIIIA.MS2 plasmid. The ligation mixture was trans-
formed into GC5 competent bacteria for propagation 
and isolation of the library DNA. Yeast strain L40coat 
stably expressing LexA-MS2 coat fusion protein was first 
transformed with pAD-Tip110 plasmid and then with 
the RNA expression library. The selection of transformed 
yeast was performed on synthetic complete plates con-
taining 0.5 mM 3-aminotriazole and no tryptophan, leu-
cine, uracil and histidine, followed by X-gal filter assay 
for β-galactosidase expression. β-galactosidase-positive 
colonies were further cultured to isolate the hybrid RNA 
plasmids.
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Recombinant protein purification
GST-Tip110, GST-Tip110s, Tip110 deletion mutants 
ΔNLS and ΔRRM, and GST proteins were expressed in 
and purified from E. coli BL21, as previously described 
[20]. Briefly, expression plasmids were transformed into 
BL21 and induced with 1  mM isopropyl-d-thiogalacto-
pyranoside for 2  h at 37°C. GST fusion proteins were 
purified using a Pierce GST fusion protein purification kit 
(Rockford, IL, USA). When necessary, GST was removed 
by treating the eluted protein with thrombin protease 
(10 units) (Invitrogen, Carlsbad, CA, USA) at room tem-
perature for 18 h. The digested protein solution was dia-
lyzed overnight in 4  l of phosphate-buffered saline and 
cleared of GST protein by additional incubations with 
fresh glutathione beads. The purified proteins were elec-
trophoresed on a 8% SDS-polyacrylamide gel and stained 
with Gold–Blue (Pierce) to ensure the complete removal 
of GST protein as well as undigested fusion protein and 
other contaminated proteins.
RNA–protein gel mobility shift assay
U6 RNA was synthesized using an Ambion in vitro tran-
scription kit (Austin, TX, USA). Briefly, pT7-U6 plasmid 
was linearized with Dra I and incubated with ATP, CTP, 
GTP and 32P-labeled UTP in the presence of T7 RNA pol-
ymerase at 30°C for 1 h, followed by removal of free nucle-
otides by an CentriSpin column (Princeton Separation, 
Princeton, NJ, USA). 32P-labeled-U6 RNA was then mixed 
with purified GST-Tip110 or its mutant proteins in a total 
volume of 20 μl containing 1 mM HEPES, pH 7.6, 1 μM 
MgCl2, 16 mM KCl, 2.5% glycerol (v/v), and 10 nM DTT. 
The mixture was incubated on ice for 15  min and then 
subjected to 5% nondenaturing polyacrylamide gel electro-
phoresis (acrylamide-bisacrylamide, 80:1) in the 0.5× TBE 
buffer. The gel was dried and exposed for autoradiography.
Preparation of pre‑mRNA and in vitro splicing assay
Human β-globin minigene pre-mRNA was synthesized 
using an Ambion in vitro capped RNA transcription kit 
(Ambion). Briefly, pSP64-Hßδ6 plasmid was linearized 
with BamH I and incubated with ATP, CTP, GTP, cap 
anolog and 32P-labeled UTP at 37°C for 2 h. 32P-labeled 
pre-mRNA was then purified on a 5% denaturing poly-
acrylamide gel and suspended in 10  mM Tris.HCl, pH 
7.9. The 32P-labeled pre-mRNA was then aliquoted and 
stored at −80°C. Splicing reactions were carried out in a 
25 μl volume containing 12.8 μM MgCl2, 500 μM ATP, 
20 mM creatine phosphate, 2.7% (w/v) polyvinyl alcohol, 
1,000 U/ml RNasin, 12.8 mM HEPES, pH 8.0, 14% (v/v) 
glycerol, 62 mM KCl, 0.12 mM EDTA, and 0.7 mM DTT 
at 30°C for 2 h. The reactions contained 6 μl Hela nuclear 
extract (Promega, Madison, WI, USA) and 12.5  ng 
32P-labeled pre-mRNA prepared above.
Monoclonal antibody production
Anti-Tip110 monoclonal antibodies were produced by 
Promab Biotechnologies, Inc. (Albany, CA, USA). Briefly, 
purified GST-Tip110 protein was used to immunize 
BALB/c mice. The mice were given an additional boost 
immunization after 3 weeks. Three days after the boost, 
the spleen cells were isolated from the immunized mice 
and fused with SP20 cells (ATCC) using polyethylene gly-
col (Sigma, St. Louis, MO, USA). Resulting hybridoma 
were screened to be specific anti-Tip110 antibody using 
ELISA. To purify the monoclonal antibody, the hybri-
doma cells were cultured in a production module of the 
miniPERM device (Viva Science, Inc.), and the antibody 
was further purified from the culture supernatant using 
a Protein A column and a AKTA prime-automated liq-
uid chromatography system (Amersham, Piscataway, NJ, 
USA). The antibody protein purity was determined to be 
IgG2 with a purity of higher than 99%.
Tip110 immunodepletion
Purified Tip110 monoclonal antibody (20  μg) was 
incubated with 50  μl of 50% slurry protein A-Sepha-
rose (Amersham) in a buffer containing 20  mM 
HEPES, pH 8.0, 100  mM KCl, 0.2  mM EDTA, 20% 
(v/v) glycerol, 0.5  mM PMSF, 1  mM DTT at 4°C for 
4 h with continuous mixing. The protein A beads were 
then recovered by centrifugation and repeated washes 
with the same incubation buffer to remove excess anti-
Tip110 antibody. An aliquot of the beads were then 
incubated with Hela nuclear extract at 4°C for 2 h with 
continuous mixing, and the supernatant was used as 
Tip110-depleted Hela nuclear extract. Tip110 protein 
on the immunoabsorbed beads was eluted by adding 
20  μl of 4× SDS sample buffer, followed by boiling 
5  min. The eluent and aliquot of the Tip110-depleted 
Hela nuclear extract were subjected to 10% SDS-
PAGE gel and Western blot analysis to ensure efficient 
Tip110 depletion.
Pre‑mRNA splicing‑dependent CAT reporter gene assay
293T cells were plated in a 6-well plate at a density of 
0.72  ×  106 cells/well and 1  day later transfected with 
1  μg pDM138, 1  μg pcRev, 1–5  μg pTip110.His or 
pTip110.siRNA. In all transfections, a CMVβGal plasmid 
was included to normalize transfection variations, and 
pcDNA3 was used to equalize the amount of transfected 
DNA. Forty-eight hours after transfection, the cells were 
harvested and subjected to 3 rounds of freeze–thaw in 
0.25  M Tris.HCl, pH 8.0, and the lysates were collected 
for β-galactosidase and CAT activities. β-galactosidase 
was determined using a colorimtric assay [20], while CAT 
was determined by one-step simple phase extraction and 
scintillation counting as described [33].
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Preparation of cell lysates and Western blot analysis
Cells were washed twice with ice-cold phosphate-buff-
ered saline (PBS), and cell pellets were suspended in 
two volumes of whole cell lysis buffer containing10 mM 
NaHPO4, 150  mM NaCl, 1% Triton X-100, 0.1% SDS, 
0.2% sodium azide, 0.5% sodium deoxycholate, 0.004% 
sodium fluoride, and 1  mM sodium orthovanadate and 
incubated on ice for 10  min. Cell lysates were obtained 
by centrifugation, removal of the cell debris, and electro-
phoretically separated on 10% SDS-PAGE and analyzed 
by immunoblotting. Anti-His antibody was from Qiagen 
(Valencia, CA, USA), while β-actin was from Santa Cruz 
Biotech. (Santa Cruz, CA, USA). The blots were first 
probed with primary antibodies, followed by appropriate 
horseradish peroxidase-conjugated secondary antibodies, 
and then visualized with the ECL system (Amersham).
RNA isolation and RNA‑Seq
Hela were transfected with human Tip110 siRNA or the 
universal control siRNA. Total RNA was purified from 
transfected cells using Trizol according to the manufac-
turer’s instructions (Life Technologies, Grand Island, 
NY, USA) and used for RNA-Seq. The RNA-Seq was 
performed at the Genomic Core of UT Southwestern 
Medical Center, Dallas, TX, USA. The RNA-Seq reads 
were aligned to the human genome sequences for further 
differential and spliceosome pathway analysis using the 
Panther Pathway Analysis software.
qRT‑PCR
Total RNA was extracted using Trizol and used to syn-
thesize cDNA using a ScriptII RT reagent kit (Promega). 
cDNAs were used for qPCR using a Power Sybr®Green 
PCR kit (Life Technologies) according to the manufac-
turer’s instructions. The qPCR program consisted of one 
cycle of 95°C for 10 min, 40 cycles of 95°C for 15 s and 
60°C for 1 min.
Results
Identification of Tip110 RNA ligands by the yeast 
three‑hybrid cloning
To determine if Tip110 bound to specific RNAs, we took 
advantage of a RNA–protein interaction-based yeast 
three-hybrid cloning strategy [34]. This genetic assay was 
initially developed to study RNA–protein interactions 
and later adapted to identify RNA ligands of an RNA 
binding protein [32]. It is based on the transcriptional 
activation of separable domains of transcriptional factors 
such as GAL4 and LexA, and is composed of two hybrid 
proteins and one hybrid RNA (Figure  1a). One hybrid 
protein consists of the DNA binding domain of tran-
scriptional activator LexA fused to a known RNA bind-
ing protein bacteriophage MS2 coat protein. The hybrid 
RNA is a RNA library expressing a MS2 coat protein 
RNA binding sequence. The other hybrid protein consists 
of the activation domain of transcriptional activator Gal4 
fused to a bait protein, in our case Tip110. Binding of the 
bait protein Tip110 to the target RNA in the RNA hybrid 
brings closer the Gal4 activation domain and the LexA 
DNA binding domain and subsequently activates expres-
sion of the reporter genes LacZ/His. We constructed 
a hybrid RNA library from 50 to 150  bp fragments of 
genomic DNA isolated from 293T cells and transformed 
it into the L40coat strain containing both LexA-MS2 
and Gal4 AD-Tip110. We then plated the transformants 
on synthetic media lacking uracil, leucine, tryptophan, 
and histidine, which are used to select for the presence 
of these three hybrids and activation of the His reporter 
gene. We also include 0.5 mM 3-aminotriazole to reduce 
a background level of His gene expression. Among an 
estimate of 11.4 million yeast transformants, about 450 
colonies were formed after 1  week. Of these, 156 were 
found to be β-galactosidase-positive. We then cultured 
these colonies in rich media to lose the Gal4 AD-Tip110 
plasmid and tested them for their ability to activate 
reporter genes. The results showed that of these 156 colo-
nies only 6 were no longer β-galactosidase-positive, while 
other 150 appeared to activate LacZ gene expression in 
Figure 1 Identification of U6 as a Tip110 binding RNA target.  
a Scheme of the yeast three-hybrid cloning strategy. LexA BD-MS2: 
LexA DNA binding domain fused with phage coat protein MS2; MS2 
RNA–RNA library: the target RNA sequence of MS2 protein was fused 
to a pool of RNAs transcribed from human genomic DNA; Gal4 AD-
Tip110: Gal4 activation domain fused to Tip110 protein. Respective 
binding of MS2 protein to MS2 target RNA and Tip110 protein to its 
putative RNAs leads to activation of LacZ and His reporter genes.  
b Sequences of RNA hits obtained from the yeast three-hybrid 
screening using Tip110 as the bait. The consensus sequence was 
matched to small nuclear U6 RNA at nucleotides 34–46.
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the absence of Gal4 AD-Tip110. Sequence analysis of 
these RNA inserts revealed a consensus of 13 nucleotides 
(nt.): gaacgauacagag (Figure 1b). We performed a BLAST 
search with the sequence, and found it to be identical to 
small nuclear RNA U6 at nt. 34–46.
Binding of Tip110 protein to U6 RNA
To ascertain Tip110 binding to U6 RNA, we synthesized 
U6 RNA in vitro in the presence of α-32P-UTP and used 
the 32P-labeled U6 RNA as a probe. We then incubated 1, 
5, 10 and 50  ng purified recombinant GST-Tip110 pro-
tein with 32P-labeled U6 RNA and determined Tip110-
U6 complex formation using a gel mobility shift assay. 
The same amounts of purified GST protein were included 
as a control in the experiments. Complex formation 
between Tip110 and U6 became evident when 5  ng 
Tip110 was added and increased significantly when more 
Tip110 protein was present (Figure  2a). There was no 
complex formation between GST and U6 in all reactions. 
To determine the specificity of Tip110 binding to U6, we 
incubated 10  ng GST-Tip110 protein with 32P-labeled 
U6 RNA in the presence of 1-, 10-, and 100-fold excess 
amount of unlabeled U6 RNA, yeast tRNA and poly(I.C) 
and determined Tip110-U6 complex formation using the 
same assay. Increasing amounts of unlabeled U6 effec-
tively competed out 32P-labeled U6 for Tip110 binding, 
as Tip110 and 32P-labeled U6 no longer formed a com-
plex in the presence of unlabeled U6 RNA (Figure  2b). 
In contrast, inclusion of U6-unrelated yeast tRNA and 
poly(I.C) had little effects on the complex formation 
between Tip110 and 32P-labeled U6 RNA. There are two 
RRMs at the C-terminal of Tip110, one at aa700–778 
and the other at aa802–874, and one nuclear localization 
signal (NLS) at aa601–650 [20]. To determine the role 
of the RRM domains in Tip110 binding to U6 RNA, we 
constructed, expressed and purified recombinant GST-
Tip110 mutant that had both RRMs deleted (ΔRRM) 
and determined its ability to bind to U6RNA. Similarly, 
we also expressed, purified and included in these experi-
ments recombinant Tip110 mutant ΔNLS containing no 
NLS and a naturally occurring small splicing variant that 
only encodes the N-terminal 365 amino acids of Tip110 
(Tip110s) [20]. Compared to Tip110, both ΔRRM and 
Tip110s showed no binding to U6 RNA, while ΔNLS 
retained the U6 binding activity (Figure  2c), suggesting 
that RRMs were directly involved in Tip110 binding to 
U6 RNA. Collectively, these results confirm the finding 
from the yeast three-hybrid cloning that Tip110 binds to 
U6 RNA in a specific manner.
Promotion of pre‑mRNA splicing by Tip110
Small nuclear U6 RNA directly participates in pre-
mRNA splicing [35]. Our early studies have shown that 
Tip110 is localized in the spliceosome-rich “speckles” 
subnuclear structure [20]. Thus, the finding of Tip110 
binding to U6 prompted us to determine the possible 
Figure 2 Specific binding of Tip110 protein to U6 RNA. a Complex formation between Tip110 and U6 RNA. 32P-labeled U6 RNA (*U6) was 
incubated with 1, 5, 10, and 100 ng recombinant GST (lanes 2–5) or GST-Tip110 (lanes 6–9). The reaction containing no recombinant protein was 
included to show free 32P-labeled U6 RNA (lane 1). The RNA–protein complex formation was determined using the electrophoretic mobility shift 
assay (EMSA). b Specificity of Tip110 binding to U6 RNA. 32P-labeled U6 RNA (*U6) was incubated with 10 ng recombinant GST-Tip110 in the pres-
ence of 5, 10, and 50 ng unlabeled U6 RNA (lanes 3–5), yeast tRNA (lanes 6–8), or polyinosinic:polycytidylic acid (poly I.C) (lanes 9–11). The complex 
formation of Tip110 and U6 RNA was determined using the EMSA. The binding reactions containing *U6 only (lane 1) and *U6 and GST-Tip110 (lane 
2) were also included. c Binding of Tip110 mutants to U6 RNA. 32P-labeled U6 RNA (*U6) was incubated with 10 ng recombinant GST-Tip110s (lane 
3), GST-ΔNLS (lane 4), or GST-ΔRRM (lane 5). The RNA–protein complex formation was determined using the EMSA. The binding reactions contain-
ing *U6 RNA only (lane 1) or *U6 RNA and GST-Tip110 (lane 2) were also included. C RNA–protein complex; F unbound free RNA.
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role of Tip110 in eukaryotic pre-mRNA splicing. We 
then performed an in vitro splicing assay using a human 
β-globin minigene pre-mRNA as a substrate. This mini-
gene encodes the first exon, the first intron, and a major 
part of the second exon of human β-globin and has 
been well characterized and widely used in the in  vitro 
splicing assay [36, 37]. We added 10 and 100  ng puri-
fied GST-Tip110 protein in the splicing reaction and 
determined its effects on the β-globin pre-mRNA splic-
ing (Figure 3a). We also included 100 ng GST protein as 
a control. Compared to the GST control, 10 and 100 ng 
GST-Tip110 increased the splicing efficiency by about 
3-fold and 12-fold, respectively (Figure  3b). We also 
added GST-Tip110s, GST-ΔNLS and GST-ΔRRM in the 
splicing reaction. GST-Tip110s only showed a very mod-
est increase in splicing, while both GST-ΔNLS and GST-
ΔRRM enhanced the pre-mRNA splicing similarly to 
that of the GST-Tip110 (Figure 3b). These results demon-
strate that Tip110-mediated pre-mRNA splicing and that 
the domain responsible for this function was located at 
the C terminus of the protein. In addition, promotion of 
pre-mRNA splicing by GST-ΔRRM suggest that Tip110 
might function in other steps of pre-mRNA splicing, at 
least in the context of the in vitro splicing assay.
Inhibition of pre‑mRNA splicing by Tip110 depletion 
and its reversal by Tip110 add‑back
To determine the significance of Tip110 function in pre-
mRNA splicing, we decided to immunodeplete Tip110 
protein from the Hela nuclear extract that was used in 
the in vitro splicing assay. Thus, we first generated anti-
human Tip110 monoclonal antibodies using recombinant 
GST-Tip110. We then incubated Hela nuclear extract 
with anti-human Tip110 antibodies and protein-A aga-
rose beads. Tip110-depleted Hela nuclear extract was 
recovered by brief centrifugation, followed by removal 
of the beads. An isotype-matched IgG was included as 
a control. Western blot analysis showed that immuno-
depletion efficiently removed Tip110 protein from Hela 
nuclear extract (Figure  4a). We used these extracts and 
performed the pre-mRNA splicing assay (Figure  4b). 
Compared to the IgG control, little splicing products 
were detected in anti-Tip110 antibody-depleted Hela 
nuclear extract (Figure 4c). To ascertain Tip110 function 
Figure 3 Human β-hemaglobin pre-mRNA splicing by Tip110 and its mutants. 32P-labeled human β-hemaglobin minigene pre-mRNA was 
incubated with Hela nuclear extract in the presence of 10 (+) or 50 ng (++) recombinant GST-Tip110 (lanes 2 and 3), GST-Tip110s (lanes 4 and 5), 
GST-ΔNLS (lanes 6 and 7), or GSTΔRRM (lanes 8 and 9). Recombinant GST protein (50 ng) was included as a control (lane 1). The reaction mixtures 
were separated on 8% denaturing PAGE (a). The symbols on the left are pre-mRNA and its splicing products. Splicing was quantitated by densitomet-
ric scanning of the intronless spliced RNA product on the autoradiography, the spliced RNA product in the reaction containing GST (lane 1) was set 
as the reference to calculate the relative level of pre-mRNA splicing (b).
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in pre-mRNA splicing, we performed the splicing assay 
by adding back GST-Tip110 protein into Tip110-depleted 
Hela nuclear extract. The results showed that Tip110 
add-back restored the splicing activity. Taken together, 
these results show that Tip110 is indispensible for consti-
tutive pre-mRNA splicing.
Correlation between Tip110 expression and pre‑mRNA 
splicing‑dependent reporter gene expression
Although pre-mRNA splicing mainly occurs in the 
nucleus, some processes involve both cytosol and nucleus 
[38]. It is clear that the in vitro splicing assay is likely not 
representative some aspects of in  vivo splicing process. 
Thus, we decided to further determine Tip110 function 
in pre-mRNA splicing in  vivo. We took advantage of a 
HIV-1 Rev-dependent reporter gene DM138 (Figure 5a) 
and determined the relationship between Tip110 expres-
sion and pre-mRNA splicing. The chloramphenicol 
acetyltransferase (CAT) reporter gene in DM138 is under 
the control of the CMV promoter, is flanked by introns 
containing splice donor and acceptor sites, and has the 
CAT gene linked to a DNA sequence encoding HIV-1 
Rev responsive element (RRE) [39, 40]. The construct 
is designed in such a manner that the CAT pre-mRNA 
transcripts contain the introns and RRE, which will not 
be exported into the cytosol from the nucleus for CAT 
protein translation unless HIV-1 Rev is provided in trans. 
We reasoned that if Tip110 enhanced pre-mRNA splic-
ing, Tip110 expression would negate HIV-1 Rev-depend-
ent expression of intron-containing pre-mRNA. Thus, we 
transfected 293T cells with DM138 alone, or in combi-
nation with HIV-1 Rev plasmid and increasing amount 
of Tip110 expression plasmid. We then determined 
CAT activity. As expected, Rev expression significantly 
improved CAT gene expression (Figure  5b). On the 
other hand, Tip110 expression decreased Rev-dependent 
CAT gene expression, and the decrease appeared to be 
dose-dependent. Furthermore, we also knocked down 
Figure 4 Effects of Tip110 immunodepletion and add-back on pre-mRNA splicing. Hela nuclear extract was pre-incubated with Tip110 mAb-con-
jugated protein-A beads to deplete endogenous Tip110 protein, as determined by Western blot analysis (a), and then used for pre-mRNA splicing 
reaction (b). An isotype-matched immunoglobulin control (IgG) was included as an immunodepletion control. Tip110-depleted nuclear extract was 
supplemented with recombinant Tip110 (100 ng) for the splicing reaction (b). Splicing was quantitated by densitometric scanning of the intronless 
spliced RNA product on the autoradiography, the spliced RNA product in the reaction containing the control IgG-immunodepleted Hela nuclear 
extract was set as the reference to calculate the relative level of pre-mRNA splicing (c).
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constitutive Tip110 expression using a Tip110 siRNA 
expression plasmid and determined its effects on CAT 
gene expression. In contrast to Tip110 over-expression, 
Tip110 knockdown increased CAT gene expression, and 
the increase was also dose-dependent (Figure  5c). The 
inverse correlation between Tip110 expression and pre-
mRNA splicing dependent CAT reporter gene expression 
confirm that Tip110 is directly involved in eukaryotic 
pre-mRNA splicing.
Requirement of Tip110 domains and pre‑mRNA splicing
Next, we performed the same reporter gene assay using 
different Tip110 deletion mutants and further examined 
the structure–function relationship of Tip110 in terms 
of pre-mRNA splicing. We transfected 293T cells with 
DM138 alone, or in combination with HIV-1 Rev plas-
mid, and Tip110s, ΔNLS, or ΔRRM expression plas-
mid. We also included full-length Tip110 and Tip110 
siRNA expression plasmids in these experiments. In 
agreement with previous results (Figure 5), Tip110 over-
expression decreased CAT gene expression (Figure 6a). 
As expected, Tip110 siRNA expression increased CAT 
gene expression. On the other hand, over-expression 
of Tip110 or ΔRRM showed no effects on CAT gene 
expression. Interestingly, over-expression of ΔNLS 
inhibited CAT gene expression, but to a lesser extent 
than that of full-length wild-type Tip110. In addition, 
we also constructed a mutant ΔLSM lacking the Lsm 
motif located between aa942–963, which has been pos-
tulated to interact with Lsm proteins to promote U4/U6 
formation [41]. Similar to Tip110s and ΔRRM, ΔLSM 
over-expression had no effects on CAT gene expres-
sion. We also performed a Western blot analysis to 
ensure comparable protein expression of Tip110 and 
its mutants (Figure  6b). These results suggest that the 
U6-binding domain RRM, the Lsm proteins-interact-
ing domain LSM, and NLS are all important for Tip110 
function in pre-mRNA splicing.
Figure 5 Effects of Tip110 expression on pre-mRNA splicing-dependent CAT reporter gene expression. A. Scheme of the HIV-1 Rev protein-
dependent intron-containing CAT reporter DM138. the CAT gene expression requires nuclear export of intron-containing (unspliced) CAT transcript 
through the interaction between HIV-1 Rev protein and Rev responsive element (RRE) within the CAT transcript. SD splice donor, SA splice acceptor. 
b 293T cells were transfected with DM138 (lane 1), DM138 and Rev (lane 2), or DM138, Rev and increasing amounts of Tip110 (lanes 3–7). The cells 
were harvested 48 h after transfection for CAT assay (top panel) or Western blot for Tip110 (bottom panel). c 293T cells were transfected with DM138 
(lane 1), DM138 and Rev (lane 2), or DM138, Rev and increasing amounts of Tip110 siRNA expression plasmids (lanes 3–7). The cells were harvested 
48 h after transfection for CAT assay (top panel) or Western blot for Tip110 (bottom panel). The amount of total DNA in all transfections was equalized 
with pcDNA3 plasmid. A CMVβGal plasmid was included to normalize the transfection variations for CAT assay, while β-actin was included to show 
equal loading (b, c). Compared to Figure 5b, c only used one fifth of DM138 reporter plasmid in the transfections.
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Presence of Tip110 in the splicing complexes
To test whether Tip110 is physically associated with 
active spliceosomes, we incubated an in  vitro splic-
ing reaction with immobilized anti-Tip110 antibody, 
immunoprecipitated the labeled RNA species in 
the splicing reaction, and analyzed the immunopre-
cipitated RNA species. An isotype-matched IgG was 
included as a control. In addition, the splicing reaction 
without any IgG was also included as a mock control. 
Compared to the mock control, no significant RNA 
species were detected in the IgG control immunopre-
cipitates (lane 2, Figure  7), whereas more unspliced 
β-globin pre-mRNA and less intron-spliced β-globin 
mRNA were detected in the anti-Tip110 immunopre-
cipitates (lane 3, Figure  7). Of note was that released 
lariat RNA species was also detected in the anti-Tip110 
immunoprecipitates. These results confirmed that 
Tip110 was associated with active spliceosomes and 
provide further support for Tip110 function in pre-
mRNA splicing.
Effects of Tip110 on global pre‑mRNA splicing
We next determined whether Tip110 expression would 
globally affect pre-mRNA splicing. We transfected Hela 
with Tip110-specific siRNA or control siRNA, isolated 
mRNA and performed the next generation RNA sequenc-
ing (RNA-Seq). The cells transfected with Tip110 siRNA 
and control siRNA were compared for the alternative 
gene spliced transcripts. Bioinformatics analysis of the 
RNA transcripts indicated that Tip110 knockdown led to 
changes of alternative spliced RNA transcripts of 17,498 
genes with statistical significant difference (p  <  0.05). 
Using the Panther pathways analysis, those genes were 
mainly grouped as the following categories: protein-
binding transcription factors (37%), catalytic molecules 
(35%), nucleic acid-binding transcription factors (9%), 
structural molecules (6%), and receptors (4%) (Figure 8a). 
Of particular note were four pre-mRNA splicing factors 
snRNP polypeptide B (SNRPB2), zinc finger RNA-bind-
ing motif and serine/arginine-rich 2 (ZRSR2), pre-mRNA 
processing factor 4 (PRPF4) and pre-mRNA processing 
factor 38b (PRPF38b) that showed all down-regulation 
in Tip110 siRNA-transfected cells (Figure 8b). qRT-PCR 
was then performed to quantify the mRNA expression 
of these four genes in Tip110 siRNA-transfected Hela as 
well as in Tip110-transfected Hela. The results showed 
the positive association between Tip110 and mRNA lev-
els of these four genes (Figure  8c). Similar results were 
obtained in 293T. Taken together, these results showed 
that Tip110 exhibited global effects on expression of host 
genes including the pre-mRNA splicing factors and sug-
gest that Tip110-induced changes in pre-mRNA splic-
ing factors may provide additional regulatory control of 
Tip110-mediated pre-mRNA splicing.
Discussion
In this study we aimed to identify the RNA targets for 
Tip110 binding. We demonstrated that Tip110 spe-
cifically interacted with small nuclear U6 RNA through 
the yeast 3-hybrid screen and RNA EMSA (Figures  1, 
2). Tip110 promoted pre-mRNA splicing in  vitro (Fig-
ure  3) and in a pre-mRNA splicing-dependent reporter 
gene assay (Figure  5). Corroborated with these findings 
were that depletion of Tip110 from nuclear extract led 
to inhibition of pre-mRNA splicing and that add-back 
Tip110 restored pre-mRNA splicing (Figure  4). Moreo-
ver, RRM domain of Tip110 was shown to be important 
for U6 RNA binding; RRM, LSM, and NLS domains were 
all important for Tip110 function in pre-mRNA splic-
ing (Figures  2, 6). Furthermore, Tip110 was detected in 
association with pre-mRNA- and spliced RNA-contain-
ing spliceosomes (Figure  7). Lastly, RNA-Seq analysis 
showed that Tip110 expression was linked to alternate 
pre-mRNA splicing of the majority of genes in human 
Figure 6 Effects of Tip110 mutants on pre-mRNA splicing-depend-
ent CAT reporter gene expression. 293T cells were transfected with 
DM138 (lane 1), DM138 and Rev (lane 2), or DM138, Rev, and Tip110 
(lane 3), Tip10 siRNA (lane 4), Tip110s (lane 5), ΔNLS (lane 6), ΔRRM 
(lane 7), or ΔLSM (lane 8). The cells were harvested 48 h after transfec-
tion for CAT assay (a) or Western blot for expression of Tip110 and 
its mutants (b). The amount of total DNA in all transfections was 
equalized with pcDNA3 plasmid. A CMVβGal plasmid was included to 
normalize the transfection variations for CAT assay, while β-actin was 
included to show equal loading.
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genome including several splicing factors (Figure  8). 
These results demonstrated that Tip110 regulated global 
pre-mRNA splicing likely through interaction with 
snRNA U6 and other splicing factors.
Biogenesis of the snRNP U1, U2, U4, U5, and U6 is a 
complex process. Newly synthesized snRNP undergo 
various modification and assembly, and then export from 
nuclear to cytoplasm where they mature and transport 
back into the Cajal bodies in the nucleus. snRNA/snRNP 
then recruit other splicing factors, undergo further 
assembly and maturation in the Cajal bodies [42–44]. 
Our current study identified U6 snRNA to be the puta-
tive Tip110-binding target through the yeast three hybrid 
cloning (Figure  1) and further confirmed the binding 
specificity through the gel shift mobility assay (Figure 2). 
These results are consistent with the previous reports 
that the U6 snRNP is targeted to the CB by specific bind-
ing to Tip110, followed by Tip110-induced assembly of 
U4/U6 snRNP for recycling of U4 and U6 snRNPs [27, 
28, 41, 45]. Tip110 has been shown to localize not only 
in Cajal bodies, and is also required for the induction of 
CB formation as well [14, 31, 46]. These studies together 
suggest that Tip110 not only targets U6 snRNP to Cajal 
bodies through direct interaction, but also is required for 
snRNP U6 assembly into mature U4/U6.U5 tri-snRNP to 
exit Cajal bodies. When we further defined the Tip110 
regions that were responsible for the snRNA U6 binding, 
we made a series of deletion mutants which including the 
C-terminal (1–350aa), deletion of NSL (Δ600–670aa), 
deletion of two RRM (Δ740–850aa). The C-terminal 
truncated protein had no binding activity at all, the dele-
tion of NSL didn’t affect the binding, but deletion of the 
two RRM could abort the binding activity to about 80% 
(Figures  2, 6). Thus, the two RRM domains are very 
important to maintain the U6 binding activity of Tip110.
Figure 7 Tip110 association with pre-mRNA and spliced RNA prod-
ucts in the spliceosomes. 32P-labeled human β-hemaglobin minigene 
pre-mRNA was first incubated with Hela nuclear extract (lane 1). The 
splicing reaction was then immunoprecipitated with an anti-Tip110 
monoclonal antibody (lane 3), or an isotype-mached IgG control (lane 
2). The immunprecipitates were subjected to 8% denaturing PAGE. 
The symbols on the left are pre-mRNA and its splicing products.
Figure 8 Tip110 global regulation on alternate pre-mRNA splicing 
and validation of Tip110-regulated four splicing factors. a Hela were 
transfected with Tip110-specific siRNA and the control siRNA. Cells 
were harvested for RNA isolation, the RNA was used for RNA-Seq. 
Panther pathway analysis was performed to group the total of 17,498 
genes with changes in alternate pre-mRNA splicing. b Four splicing 
factors were down-regulated at the mRNA level from RNA-Seq.  
c qRT-PCR was performed to validate these four mRNA expression 
from Hela and 293T that were either transfected with Tip110 expres-
sion vector and siRNA for Tip110. cDNA3 was included as the control 
for Tip110; siRNA control was included as the control for Tip110 siRNA. 
The fold changes were calculated using the control as the reference 
(b, c).
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After exiting Cajal bodies, mature snRNP enter nuclear 
speckles. Nuclear speckles are sites for pre-mRNA splic-
ing that serve as storage and/or modification sites for 
splicing factors [47]. Our previous digital fluorescence 
microscopic imaging revealed that Tip110 was detected 
within the nuclear speckle structure [20]. Tip110 may 
shuttle from Cajal bodies to nuclear speckles, likely along 
with the mature spliceosomes for pre-mRNA splicing, 
as both Cajal bodies and nuclear speckles are enriched 
in the snRNP U1, U2, U4, U5, and U6 [48]. Tip110 was 
shown to bind to RNPS1 at its C terminus and could 
be involved in constitutive and alternative pre-mRNA 
splicing [16]. RNPS1 is expressed in nuclear speckles 
and found in the active spliceosomes and functions as 
a general activator of pre-mRNA splicing [49, 50]. Our 
current study showed that Tip110 played important func-
tions in pre-mRNA splicing (Figures  3, 4, 5) and was 
present in the spliceosomes (Figure  7). Therefore, it is 
likely that Tip110 interaction with RNPS1 and co-local-
ization in nuclear speckles structure are also important 
for Tip110 function in pre-mRNA splicing. Transcrip-
tion and pre-mRNA splicing are believed to be coupled 
by the C-terminal domain (CTD) of the large subunit 
of RNA polymerase II (Pol II) [1]. CTD phosphoryla-
tion is required for the stimulatory effect of the CTD on 
splicing [51, 52]. We have previously shown that Tip110 
bound to the C-terminal domain of unphosphorylated 
RNA polymerase II in a direct and specific manner and 
Tip110 expression was associated with increased phos-
phorylation of serine 2 of the heptapeptide repeats within 
the RNAPII C-terminal domain [21]. Thus, Tip110 asso-
ciation with unphosphorylated RNAPII CTD provides 
another line of evidence to support direct involvement 
and function of Tip110 in pre-mRNA splicing.
To further determine the significance of Tip110 
involvement in pre-mRNA splicing, we performed 
RNA-Seq analysis of the alternate pre-mRNA splicing 
transcripts. As expected, Tip110 knockdown led to alter-
ations in a large number of the gene transcripts includ-
ing four known genes in pre-mRNA splicing (Figure  8). 
Tip110 knockdown significantly decreased expression 
of PRPF4, PRPF38b, SNRPB2, and ZRSR2. PRPF4 is a 
component of the U4/U6 di-snRNP and the U4/U6.U5 
tri-snRNP and is important for maintaining the pre-
mRNA splicing efficiency [53]. SNRPB2 is also important 
for maintaining the pre-mRNA splicing efficiency [54]. 
ZRSR2 is a splicing factor engaged in the initial steps of 
pre-mRNA splicing, including 3′ splice-site recognition 
[55]. PRPF38b interacts (directly or indirectly) with at 
least one of the U6 snRNA-containing snRNP complexes 
and is required for pre-mRNA splicing [56]. These find-
ings suggest that Tip110 regulation of these key pre-
mRNA splicing factors, is, if not more, as important as 
its interaction with snRNA U6 in pre-mRNA splicing. 
Tip110 is barely detectable in normal tissue and cells 
and highly elevated in tumors and differentiating stem 
cells [20, 25]. Thus, it is possible that Tip110 function 
in pre-mRNA splicing is evident only in cancerous cells 
and tumors through which elevated Tip110 expression 
causes changes in pre-mRNA splicing and gene expres-
sion and subsequent stem cell differentiation and malig-
nant transformation.
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